Inhibitory Effect and Mechanism of the Down-Regulation of TRIM32 in Colorectal Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Tripartite motif-containing protein 32 (TRIM32) is implicated in various cancers and associated with poor patient prognosis.
• The specific role and mechanism of TRIM32 in colorectal cancer (CRC) remain largely undefined.
• Understanding TRIM32's function is crucial for developing targeted therapies for CRC.

Purpose of the Study:

• To investigate the expression patterns and prognostic significance of TRIM32 in colorectal cancer (CRC).
• To elucidate the functional role of TRIM32 in CRC cell proliferation, migration, and apoptosis.
• To explore the underlying molecular mechanisms, particularly the involvement of the NF-κB signaling pathway.

Main Methods:

• Bioinformatic analysis of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases for TRIM32 expression and prognostic value in CRC.
• In vitro studies using real-time quantitative PCR, Western blotting, and cell proliferation assays on CRC cell lines (HCT116, SW480) with TRIM32 knockdown.
• In vivo assessment in xenograft mouse models evaluating tumor growth, histology (H&E), and proliferation marker (Ki67) after TRIM32 down-regulation.

Main Results:

• TRIM32 is significantly upregulated in multiple cancers and serves as a prognostic biomarker for CRC.
• Down-regulation of TRIM32 in CRC cells led to increased IκBα and decreased TRIM32, p-p65, Bcl-2, and IKKβ expression.
• Inhibition of TRIM32 suppressed CRC cell proliferation, migration, and apoptosis, and reduced tumor growth in vivo by hindering NF-κB pathway activation.

Conclusions:

• TRIM32 overexpression is a significant factor in colorectal cancer development and progression.
• TRIM32 promotes CRC tumorigenesis, partly through the activation of the NF-κB signaling pathway.
• Targeting TRIM32 presents a promising therapeutic strategy for colorectal cancer treatment.